Treatable Traits in COPD: A Precision Medicine Framework

COPD management should shift from a one-size-fits-all approach to identifying and treating specific treatable traits—clinically relevant, identifiable, and modifiable characteristics that drive symptoms, exacerbations, and poor outcomes in individual patients. 1

Core Concept

The treatable traits strategy recognizes that COPD is not a single disease but a heterogeneous syndrome where different underlying mechanisms produce varied clinical presentations. 1 Rather than treating all patients identically based solely on spirometry, this approach identifies specific pulmonary, extrapulmonary, and behavioral traits that can be targeted with evidence-based interventions. 2, 3

A critical distinction: some COPD "phenotypes" may not be stable entities but rather treatable characteristics that can change with therapy, making the treatable traits framework more clinically useful than rigid phenotypic classification. 1

Major Pulmonary Treatable Traits

1. Frequent Exacerbations

Definition: ≥2 moderate or ≥1 severe exacerbation requiring hospitalization in the previous 12 months. 4
Intervention: Single-inhaler triple therapy (LAMA/LABA/ICS) is the first-line treatment for high-risk exacerbators with CAT ≥10 or mMRC ≥2 and FEV₁ <80% predicted. 4
Mortality benefit: Triple therapy reduces all-cause mortality with risk ratios of 0.58–0.64 (NNT=4), making it the only pharmacologic intervention proven to improve survival in COPD. 4
Eosinophil-guided decisions: In patients with blood eosinophils ≥300 cells/µL, do not withdraw ICS when exacerbation risk is high; conversely, avoid escalating to triple therapy in patients with eosinophils <100 cells/µL and instead consider azithromycin or N-acetylcysteine. 4, 5

2. Chronic Bronchitis and Productive Cough

Definition: Daily productive cough for ≥3 months in two consecutive years. 2, 5
Interventions:
- Roflumilast (PDE-4 inhibitor) for patients with FEV₁ <50% predicted and exacerbation history reduces moderate and severe exacerbations. 4
- N-acetylcysteine (600 mg twice daily) or carbocysteine reduce exacerbation risk, particularly in patients with low eosinophil counts not suitable for ICS. 4, 5
- Prophylactic azithromycin (250 mg daily or 500 mg three times weekly) in former smokers with recurrent exacerbations despite optimal inhaled therapy, with monitoring for antimicrobial resistance and ototoxicity. 4

3. Type 2 Eosinophilic Inflammation

Identification: Blood eosinophils ≥300 cells/µL predict greater ICS responsiveness. 4
Intervention: Maintain ICS-containing regimens (preferably triple therapy) in symptomatic patients with elevated eosinophils and exacerbation history. 4
Caution: ICS must never be used as monotherapy in COPD due to increased pneumonia risk without exacerbation benefit. 4

4. Asthma-COPD Overlap (ACOS)

Characteristics: Increased reversibility of airflow obstruction, eosinophilic inflammation, more frequent exacerbations, wheezing, and dyspnea compared to typical COPD. 1
Intervention: ICS-containing regimens are particularly responsive in this subgroup, though prospectively validated diagnostic criteria remain lacking. 1

5. Airflow Limitation and Hyperinflation

Intervention: LAMA/LABA dual bronchodilator therapy provides superior improvements in dyspnea, exercise tolerance, and health status compared to monotherapy. 4
Initial therapy: For patients with CAT ≥10, mMRC ≥2, and FEV₁ <80% predicted, start dual bronchodilator therapy directly rather than stepwise escalation. 4
Monotherapy: For mild symptoms (CAT <10, mMRC=1) and FEV₁ ≥80% predicted, initiate LAMA (preferred) or LABA monotherapy. 4

6. Bronchiectasis with COPD Overlap (BCO)

Recognition: CT imaging reveals bronchial wall thickening and airway dilation. 6
Intervention: Mucolytics (N-acetylcysteine), airway clearance techniques, and consideration of prophylactic antibiotics for recurrent infections. 5, 6

7. Neutrophilic Inflammation

Identification: Elevated sputum or blood neutrophils, often with low eosinophils. 5, 3
Intervention: Roflumilast or macrolide antibiotics (azithromycin) may reduce exacerbations in this subgroup. 4, 5

Extrapulmonary Treatable Traits

8. Cardiovascular Disease

Prevalence: Highly prevalent comorbidity requiring integrated management. 1
Intervention: Optimize cardiovascular medications; avoid non-selective beta-blockers that worsen bronchospasm, but cardioselective beta-blockers are safe and reduce mortality. 1

9. Anxiety and Depression

Recognition: Formal screening using validated tools (e.g., Hospital Anxiety and Depression Scale). 1
Intervention: Cognitive-behavioral therapy, pulmonary rehabilitation (which improves psychological outcomes), and pharmacotherapy (SSRIs/SNRIs) when indicated. 1

10. Nutritional Deficiency and Cachexia

Identification: BMI <21 kg/m² or unintentional weight loss >5% in 6 months. 1, 6
Intervention: Nutritional supplementation combined with pulmonary rehabilitation and resistance training to improve muscle mass and functional capacity. 1

11. Osteoporosis

Risk factors: ICS use, smoking, low BMI, systemic inflammation. 1
Intervention: Bone density screening (DEXA) in high-risk patients; calcium, vitamin D supplementation, and bisphosphonates when indicated. 1

12. Metabolic Syndrome and Diabetes

Prevalence: Common comorbidity affecting 20–50% of COPD patients. 1
Intervention: Optimize glycemic control; systemic corticosteroids during exacerbations require glucose monitoring and adjustment of diabetic medications. 1

Behavioral and Environmental Treatable Traits

13. Active Smoking

Intervention: Smoking cessation is the single most important intervention, modifying disease trajectory and improving survival. 4
Pharmacotherapy: Varenicline, bupropion, or nicotine replacement therapy raise long-term quit rates to approximately 25%. 4
Caution: Current smokers have higher pneumonia risk with ICS-containing regimens. 4

14. Occupational and Environmental Exposures

Identification: Detailed exposure history to biomass fuels, dust, chemicals, and fumes. 6
Intervention: Eliminate ongoing exposures through workplace modifications or relocation; use of protective equipment. 6

15. Poor Inhaler Technique

Recognition: Common cause of treatment failure; requires assessment at every visit. 4
Intervention: Regular verification and training on proper inhaler technique; avoid prescribing multiple devices with differing techniques, which increases exacerbations and medication errors. 4
Device selection: Single-inhaler devices (e.g., single-inhaler triple therapy) are preferred to enhance adherence and reduce technique errors. 4

16. Physical Inactivity and Deconditioning

Intervention: Pulmonary rehabilitation is strongly recommended for all symptomatic patients (GOLD groups B, C, D) to improve exercise capacity, reduce dyspnea, and enhance quality of life. 1, 4
Timing: Initiate within 3 weeks after hospital discharge for exacerbations; avoid starting during acute hospitalization. 1

Implementing the Treatable Traits Approach

Phase 1: Initial Focused Assessment (All Patients)

This phase should be implemented in both primary care and hospital settings. 2

Symptom burden: Use CAT or mMRC scores at every visit. 4
Exacerbation history: Document frequency and severity over the preceding 12 months. 4
Spirometry: Confirm diagnosis (post-bronchodilator FEV₁/FVC <0.70) and assess severity. 4
Blood eosinophils: Guide ICS decisions (thresholds: <100–300, ≥300 cells/µL). 4
Smoking status: Assess current use and offer cessation interventions. 4
Comorbidities: Screen for cardiovascular disease, anxiety/depression, osteoporosis, and diabetes. 1
Inhaler technique: Verify at every visit. 4

Phase 2: Specialized Assessment (Selected Patients)

Progress to this phase if patients present with advanced disease at diagnosis, progress despite initial treatment, or have unexplained symptoms. 2

High-resolution CT chest: Identify emphysema distribution, bronchiectasis, or lung cancer. 2, 3
Sputum culture and sensitivity: For recurrent infections or suspected bronchiectasis. 2
Echocardiography: Assess for pulmonary hypertension and cor pulmonale. 1
Cardiopulmonary exercise testing: Differentiate cardiac vs. pulmonary limitations. 2
Alpha-1 antitrypsin levels: In patients <45 years, lower-lobe emphysema, or family history. 1
6-minute walk test: Quantify exercise capacity (minimally significant change: ≥53 meters). 1

Applying Treatable Traits to Exacerbation Prevention

Many treatable traits directly correlate with exacerbation risk, making this strategy inherently proactive. 2

High eosinophils + exacerbation history: Triple therapy. 4
Low eosinophils + chronic bronchitis: Roflumilast, N-acetylcysteine, or azithromycin. 4, 5
Bronchiectasis: Airway clearance, mucolytics, prophylactic antibiotics. 5, 6
Poor inhaler technique: Correct technique, simplify regimen. 4
Smoking: Cessation interventions. 4
Deconditioning: Pulmonary rehabilitation. 1, 4

Safety Considerations and Common Pitfalls

Never use ICS monotherapy: Increases pneumonia risk without exacerbation benefit. 4
Do not withhold ICS from high-risk exacerbators due to pneumonia concerns: Mortality and exacerbation benefits outweigh risks (NNT=4 vs. NNH=33). 4
Do not delay triple therapy in high-risk patients: Starting with dual therapy postpones the mortality benefit. 4
Avoid multiple inhaler devices: Increases exacerbations and medication errors. 4
Monitor for ICS side effects: Pneumonia (especially in smokers, age ≥55, BMI <25, prior pneumonia), oral candidiasis, dysphonia, and osteoporosis. 4
Azithromycin monitoring: Check baseline ECG (QTc prolongation risk), audiometry (ototoxicity), and counsel on antimicrobial resistance. 4

Advanced Interventions for Refractory Disease

Long-term oxygen therapy: Indicated for resting PaO₂ ≤55 mmHg or SaO₂ ≤88% confirmed twice ≥3 weeks apart; improves survival. 1, 4
Non-invasive ventilation: Strong recommendation for acute or acute-on-chronic respiratory failure during exacerbations. 1
Lung volume reduction: Surgical or bronchoscopic (endobronchial valves, coils) for selected patients with heterogeneous or homogeneous emphysema and significant hyperinflation refractory to optimized medical therapy. 4
Lung transplantation: Consider for progressive disease with BODE index 5–6, PaCO₂ >50 mmHg or PaO₂ <60 mmHg, and FEV₁ <25% predicted. 4

Prognostic Assessment

Use composite measures rather than FEV₁ alone to predict outcomes. 1

BODE index (Body mass index, airflow Obstruction, Dyspnea, Exercise capacity): Significant predictor of exacerbations, hospitalization, quality of life, and all-cause mortality. 1
BODEx index: Replaces exercise capacity with exacerbation history; simplifies evaluation in GOLD stage I–II disease with no decrement in mortality prediction. 1

Multidisciplinary Management

A simultaneous multidimensional assessment integrating comorbidities and systemic effects is essential. 1

Respiratory nurse specialists: Inhaler training, self-management education, exacerbation action plans. 1
Physiotherapy: Airway clearance techniques, exercise prescription, pulmonary rehabilitation. 1
Occupational therapy: Home modifications, energy conservation techniques. 1
Palliative care: For advanced disease with refractory dyspnea, consider opioids (morphine) for symptom relief. 1
Social services: Assess need for home support, oxygen equipment, and disability benefits. 1

Vaccination

Annual influenza vaccination: Recommended for all COPD patients. 4
Pneumococcal vaccination: PCV13 followed by PPSV23 for all individuals ≥65 years. 4

Future Directions

Prospective validation of the treatable traits strategy in randomized controlled trials is needed to establish its superiority over traditional COPD management. 2, 7 Biomarker identification for treatment-responsive subgroups, earlier diagnosis strategies, and novel therapies (inhaled PDE3/4 inhibitors, single-molecule dual bronchodilators, anti-inflammatory agents, gene editing) are expected to enhance precision medicine in COPD. 6

What are the treatable traits in chronic obstructive pulmonary disease and the recommended evidence‑based interventions for each?

Help us tailor your experience